Adriana G Ioachimescu1,2, Talin Handa3, Neevi Goswami4, Adlai L Pappy5, Emir Veledar6, Nelson M Oyesiku7,8. 1. Dept of Medicine (Endocrinology), Emory School of Medicine, 1365 B Clifton Rd, Atlanta, GA, 30322, USA. aioachi@emory.edu. 2. Dept of Neurosurgery, Emory School of Medicine, 1365 B Clifton Rd, Atlanta, GA, 30322, USA. aioachi@emory.edu. 3. Emory College of Arts and Sciences, 1557 Dickey Dr., Atlanta, GA, 30322, USA. 4. Georgia Institute of Technology, North Ave NE, Atlanta, GA, 30332, USA. 5. Emory School of Medicine, 201 Dowman Dr., Atlanta, GA, USA. 6. Baptist Health South Florida, Miami-Dade, USA. 7. Dept of Medicine (Endocrinology), Emory School of Medicine, 1365 B Clifton Rd, Atlanta, GA, 30322, USA. 8. Dept of Neurosurgery, Emory School of Medicine, 1365 B Clifton Rd, Atlanta, GA, 30322, USA.
Abstract
PURPOSE: To evaluate the impact of gender and year at surgery on clinical presentation and postoperative outcomes in acromegaly. METHODS: Retrospective review of patients operated between 1994 and 2016 to compare presentation and outcomes in groups defined by gender and year of surgery. Kaplan-Meier survival analyses with a composite endpoint (recurrence, reoperation, and radiation) were used for gender comparison and Youden indices for biochemical remission rates changes during study period. RESULTS: Primary indications for evaluation were phenotype, neurological symptoms, incidentaloma, hypogonadism, and galactorrhea. At surgery, men (N = 54) were younger (43.6 ± 12.7 years) than women (N = 58, 48.7 ± 12.3, P = 0.04). Male:female ratios before and after age 50 were 1.4 and 0.6 respectively. Men had higher mean IGF-1 levels (874 ± 328 vs 716 ± 296, P < 0.01) and smaller tumors (1.8 ± 1.3 cm vs 2.3 ± 1.5, P = 0.04). Postoperative remission rates were comparable (51% men, 56% women) and inversely associated with cavernous sinus invasion and GH levels. Women had longer mean follow-up (5.2 ± 3.4 years vs 3.6 ± 3.6 men, P = 0.02) and longer endpoint-free survival (P < 0.01). At last follow-up, 89.6% women and 70% men had normal IGF-1 levels (P = 0.03). Postoperative remission rates were higher in patients operated after February 15, 2011 (67.35 vs 43.5% previously, P = 0.01). In late vs early surgery group, physical changes as main indication for screening decreased (54 vs 30%, P < 0.01), while incidentaloma and hypogonadism increased. Median GH levels were lower in late vs early surgery group (P = 0.03). CONCLUSION: We demonstrate gender-specific characteristics and an evolving spectrum of clinical presentation with implications for earlier diagnosis and personalized management of acromegaly.
PURPOSE: To evaluate the impact of gender and year at surgery on clinical presentation and postoperative outcomes in acromegaly. METHODS: Retrospective review of patients operated between 1994 and 2016 to compare presentation and outcomes in groups defined by gender and year of surgery. Kaplan-Meier survival analyses with a composite endpoint (recurrence, reoperation, and radiation) were used for gender comparison and Youden indices for biochemical remission rates changes during study period. RESULTS: Primary indications for evaluation were phenotype, neurological symptoms, incidentaloma, hypogonadism, and galactorrhea. At surgery, men (N = 54) were younger (43.6 ± 12.7 years) than women (N = 58, 48.7 ± 12.3, P = 0.04). Male:female ratios before and after age 50 were 1.4 and 0.6 respectively. Men had higher mean IGF-1 levels (874 ± 328 vs 716 ± 296, P < 0.01) and smaller tumors (1.8 ± 1.3 cm vs 2.3 ± 1.5, P = 0.04). Postoperative remission rates were comparable (51% men, 56% women) and inversely associated with cavernous sinus invasion and GH levels. Women had longer mean follow-up (5.2 ± 3.4 years vs 3.6 ± 3.6 men, P = 0.02) and longer endpoint-free survival (P < 0.01). At last follow-up, 89.6% women and 70% men had normal IGF-1 levels (P = 0.03). Postoperative remission rates were higher in patients operated after February 15, 2011 (67.35 vs 43.5% previously, P = 0.01). In late vs early surgery group, physical changes as main indication for screening decreased (54 vs 30%, P < 0.01), while incidentaloma and hypogonadism increased. Median GH levels were lower in late vs early surgery group (P = 0.03). CONCLUSION: We demonstrate gender-specific characteristics and an evolving spectrum of clinical presentation with implications for earlier diagnosis and personalized management of acromegaly.
Entities:
Keywords:
Acromegaly; Gender; Growth hormone; Incidentaloma; Remission; Surgery
Authors: Tomas Thor Agustsson; Tinna Baldvinsdottir; Jon G Jonasson; Elinborg Olafsdottir; Valgerdur Steinthorsdottir; Gunnar Sigurdsson; Arni V Thorsson; Paul V Carroll; Márta Korbonits; Rafn Benediktsson Journal: Eur J Endocrinol Date: 2015-11 Impact factor: 6.664
Authors: A Ciresi; M C Amato; R Pivonello; E Nazzari; L F Grasso; F Minuto; D Ferone; A Colao; C Giordano Journal: J Clin Endocrinol Metab Date: 2012-11-15 Impact factor: 5.958
Authors: Jeremy R Anthony; Ula Abed Alwahab; Naman K Kanakiya; Diana M Pontell; Emir Veledar; Nelson M Oyesiku; Adriana G Ioachimescu Journal: Endocr Pract Date: 2015-06-29 Impact factor: 3.443
Authors: Antonio Mestron; Susan M Webb; Ricardo Astorga; Pedro Benito; Miguel Catala; Sonia Gaztambide; Jose-Manuel Gomez; Irene Halperin; Tomas Lucas-Morante; Basilio Moreno; Gabriel Obiols; Pedro de Pablos; Concha Paramo; Antonio Pico; Elena Torres; Cesar Varela; Jose-Antonio Vazquez; Juana Zamora; Merce Albareda; Montserrat Gilabert Journal: Eur J Endocrinol Date: 2004-10 Impact factor: 6.664
Authors: Maria Fleseriu; Beverly M K Biller; Pamela U Freda; Monica R Gadelha; Andrea Giustina; Laurence Katznelson; Mark E Molitch; Susan L Samson; Christian J Strasburger; A J van der Lely; Shlomo Melmed Journal: Pituitary Date: 2020-10-20 Impact factor: 4.107
Authors: David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku Journal: Front Endocrinol (Lausanne) Date: 2022-08-04 Impact factor: 6.055
Authors: Agnieszka Tomasik; Maria Stelmachowska-Banaś; Maria Maksymowicz; Izabella Czajka-Oraniec; Dorota Raczkiewicz; Grzegorz Zieliński; Jacek Kunicki; Wojciech Zgliczyński Journal: Front Endocrinol (Lausanne) Date: 2022-09-16 Impact factor: 6.055